ThinkCyte announced the completion of a Series C funding round. Including the equity funding secured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 million. This extension round was led by Japan Green Investment Corp. for Carbon Neutrality (JICN), KIRIN-GB Fund I L.P., and SMBC Venture Capital No. 7 Investment Limited Partnership. And the company also secured a loan from Japan Finance Corporation.
This latest funding round brings ThinkCyte’s total funding to $91 million, reinforcing the company’s commitment to expanding the global reach of its flagship product VisionSort. And since launching in June 2023, VisionSort has been adopted by major biopharmaceutical companies and leading academic institutions worldwide.
This new funding round will drive production and manufacturing scale-up and help accelerate global commercial expansion. With this stable footing, ThinkCyte is prepared to broaden the impact of its technologies, drive advancements in the life sciences, and maintain its leadership in innovative single-cell analysis and sorting solutions.
ThinkCyte’s goal is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enables the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.
ThinkCyte was founded in 2016 with offices in Tokyo, Japan and Redwood City, California.
